January 26, 2017

SAN DIEGO – Five studies highlighting notable research on survivorship care will be presented at the 2017 Cancer Survivorship Symposium, taking place January 27-28 at the Manchester Grand Hyatt in San Diego. These select abstracts provide a better understanding of the risks associated with treatment and the late effects of cancer.

January 26, 2017

ALEXANDRIA, Va. – Co-sponsors of the 2017 Genitourinary Cancers Symposium announced today three abstracts to be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 13, 2017, from 12:00 noon – 1:30 PM (ET).

January 24, 2017

On January 24, 2017, the Journal of the American Medical Association (JAMA), published “Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014” by Modak et al. The study found that cancer deaths in the U.S. declined by 20 percent from 1980-2014, but there were large differences in cancer mortality as well as areas with unusually higher mortality rates across counties. The following is a statement from Daniel F. Hayes, MD, FACP, FASCO, President of the American Society of Clinical Oncology (ASCO).

January 23, 2017

ALEXANDRIA, Va. – In the United States, thyroid cancer incidence is increasing more rapidly than any other cancer and is commonly diagnosed at a younger age than most adult cancers. This year, an estimated 64,300 adults in the United States will be diagnosed with the disease. 

January 23, 2017

ALEXANDRIA, Va. – A new analysis finds that 42% of partners of young breast cancer survivors experience anxiety, even several years after their partner’s cancer diagnosis.  Researchers note that ineffective (maladaptive) coping strategies, parenting concerns, and other factors were associated with anxiety. The findings are part of a growing body of research on the effects of a cancer diagnosis on caregivers and family members, and reinforce the need for greater caregiver support, which has implications for their own, as well as survivors’ health and quality of life. The data will be presented as part of the upcoming 2017 Cancer Survivorship Symposium in San Diego.

January 18, 2017

SAN FRANCISCO – Six abstracts exploring key issues in the treatment of gastrointestinal cancers will be presented at the 2017 Gastrointestinal Cancers Symposium, taking place January 19-21 at the Moscone West Building in San Francisco. 

January 11, 2017

Alexandria, Va. – The American Society of Clinical Oncology (ASCO) released, “ASCO Principles for Patient-Centered Healthcare Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. healthcare delivery landscape. The principles aim to assist the new Congress and Administration, so, as they consider the critical underpinnings of any healthcare reform proposal, the needs of patients facing a cancer diagnosis are met.

December 5, 2016

ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that George A. Komatsoulis, Ph.D., will be its first Chief of Bio-Informatics. This marks another step toward the organization's goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records (EHR), breaking down silos among various EHR systems and providers, and securely processing and analyzing the data to give personalized insights than can improve the quality of care for patients with cancer.

November 30, 2016

Alexandria, Va. – CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology® (ASCO), today announced CancerLinQ Discovery™, a groundbreaking offering that will provide insights through the analysis of real-world cancer care data. CancerLinQ Discovery will provide highly curated, de-identified sets of clinical data with the objective of creating new clinical knowledge and improving patient outcomes. It will derive these sets from the rapidly-growing CancerLinQ® database, which now includes over 1.5 million patient records and more than 70 oncology practices that have agreed to contribute data to CancerLinQ’s core quality improvement and data-sharing platform.

November 16, 2016

More than 100 participants are now enrolled on study drug in the American Society of Clinical Oncology’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial launched in March 2016 at 37 sites and this month welcomes its newest participating clinical sites: Cancer Treatment Centers of America®, Intermountain Healthcare, Sanford Health, Swedish Cancer Institute and Providence Health & Services, and University of Nebraska Medical Center for a total of 63 participating sites in 15 states.

November 15, 2016

ALEXANDRIA, VA – A new collaboration between the American Society of Clinical Oncology (ASCO) and the American Board of Internal Medicine (ABIM) will enable participants of ASCO’s Quality Oncology Practice Initiative (QOPI®) and the QOPI Certification Program (QCP) to receive Maintenance of Certification (MOC) Practice Assessment points from ABIM.

October 20, 2016

ALEXANDRIA, Va. – CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), announced today that more than one million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists.

July 14, 2016

The American Society of Clinical Oncology (ASCO) announced today the 14 practices participating in the 2016 Quality Training Program. The program is designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and administrative processes and outcomes.

June 6, 2016

The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, joining six other companies in ASCO’s first-ever clinical trial. Since opening on March 14, 2016, 18 participants have enrolled and are receiving study treatment, and 31 more have provided consent and are in, or have completed, the screening process. These numbers continue to grow daily.

June 5, 2016

A randomized phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole (Femara) from 5 to 10 years. Following five years of an AI and any duration of prior tamoxifen, women who received letrozole for five additional years had a 34% lower risk of recurrence than those who received placebo. The trial was led by the Canadian Cancer Trials Group with participation from the National Clinical Trials Network.

Pages